MedTrace Logo

Immunogenicity and Safety of 2 Doses of Live Attenuated Varicella Vaccine

NCT02173899 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 716

Last updated 2014-09-01

No results posted yet for this study

Summary

The purpose of this study is to observe the occurrence of adverse events, seroconversion rate and geometric mean titres(GMTs) of 2 doses of live attenuated varicella vaccine.

Conditions

  • Varicella

Interventions

BIOLOGICAL

varicella-1

Give the second varicella vaccine (a single 0.5 ml) and get blood samples at 0, 35-42 day

BIOLOGICAL

varicella-3

Give the second varicella vaccine (a single 0.5 ml) and get blood samples at 0, 35-42 day

BIOLOGICAL

varicella-5

Give the second varicella vaccine (a single 0.5 ml) and get blood samples at 0, 35-42 day

Sponsors & Collaborators

  • Guangdong Provincial Institute of Biological Products And Materia Medica

    collaborator OTHER

  • Changchun Keygen Biological Products Co., Ltd.

    lead OTHER

Principal Investigators

  • Huizhen Zheng, Master · Guangdong Center for Disease Prevention and Control

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
7 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2014-08-31
Completion
2014-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02173899 on ClinicalTrials.gov